Side effects across medicines
Medicines whose labels list gait disturbance
55 medicines have an FDA label that names gait disturbance in its boxed warning, warnings, adverse reactions, trial table, patient leaflet or Drug Facts “stop use” warning (of the labels PlainMeds reads: each medicine's quoted label and up to eight more, by route and wording). Among them, the most FAERS reports of gait disturbance name pimavanserin (2,192), sertraline (1,884) and duloxetine (1,515), through July 30, 2026. A label lists what its studies and reports found, and a report does not show that a medicine caused the event.
Check it at the source: the FDA FAERS public dashboard; FDA labels on DailyMed.
Which medicines' labels list gait disturbance?
Ordered by where the label names it, the boxed warning first, then by FAERS reports. A medicine whose own indications name it, because it treats it, is not counted.
| Medicine | Where a label names it | FAERS reports of gait disturbance |
|---|---|---|
| Pimavanserin | adverse reactions | 2,192 |
| Sertraline | adverse reactions | 1,884 |
| Duloxetine | adverse reactions | 1,515 |
| Risperidone | adverse reactions | 1,331 |
| Rivastigmine | adverse reactions (transdermal label) | 736 |
| Lacosamide | adverse reactions | 632 |
| Botulinum toxin type a | adverse reactions (intradermal/ | 554 |
| Lithium | adverse reactions | 472 |
| Valbenazine | adverse reactions | 467 |
| Aprepitant | adverse reactions (intravenous label) | 291 |
| Cenobamate | adverse reactions | 281 |
| Cannabidiol | adverse reactions | 221 |
| Perampanel | adverse reactions | 207 |
| Febuxostat | adverse reactions | 139 |
| Paricalcitol | adverse reactions (intravenous label) | 135 |
| Lumateperone | adverse reactions | 111 |
| Lorlatinib | adverse reactions | 87 |
| Artemether and lumefantrine | adverse reactions | none in the top 1,000 |
| Asparaginase | adverse reactions | none in the top 1,000 |
| Cedazuridine and decitabine | adverse reactions | none in the top 1,000 |
| Ceritinib | adverse reactions | none in the top 1,000 |
| Crizotinib | adverse reactions | none in the top 1,000 |
| Daratumumab and hyaluronidase | adverse reactions | none in the top 1,000 |
| Dasatinib | adverse reactions | none in the top 1,000 |
| Deferiprone | adverse reactions | none in the top 1,000 |
| Difelikefalin | adverse reactions | none in the top 1,000 |
| Dordaviprone | adverse reactions | none in the top 1,000 |
| Edaravone | adverse reactions | none in the top 1,000 |
| Elapegademase | adverse reactions | none in the top 1,000 |
| Elranatamab | adverse reactions | none in the top 1,000 |
| Entrectinib | adverse reactions | none in the top 1,000 |
| Epcoritamab | adverse reactions | none in the top 1,000 |
| Ertapenem | adverse reactions | none in the top 1,000 |
| Eslicarbazepine | adverse reactions | none in the top 1,000 |
| Esomeprazole and naproxen | adverse reactions | none in the top 1,000 |
| Fenfluramine | adverse reactions | none in the top 1,000 |
| Fexinidazole | adverse reactions | none in the top 1,000 |
| Flibanserin | adverse reactions | none in the top 1,000 |
| Fluvoxamine | adverse reactions | none in the top 1,000 |
| Ganaxolone | adverse reactions | none in the top 1,000 |
| Iberdomide | adverse reactions | none in the top 1,000 |
| Ifosfamide | adverse reactions | none in the top 1,000 |
| Interferon gamma 1b | adverse reactions | none in the top 1,000 |
| Ivosidenib | adverse reactions | none in the top 1,000 |
| Lunsotogene parvec | adverse reactions | none in the top 1,000 |
| Mosunetuzumab | adverse reactions (intravenous label) | none in the top 1,000 |
| Praziquantel | adverse reactions | none in the top 1,000 |
| Repotrectinib | adverse reactions | none in the top 1,000 |
| Talquetamab | adverse reactions | none in the top 1,000 |
| Teclistamab | adverse reactions | none in the top 1,000 |
| Thiotepa | adverse reactions | none in the top 1,000 |
| Tisotumab vedotin | adverse reactions | none in the top 1,000 |
| Vigabatrin | adverse reactions | none in the top 1,000 |
| Vinorelbine | adverse reactions | none in the top 1,000 |
| Amantadine | trial table | 899 |
Source: FDA drug labels via openFDA, read October 8, 2026; FAERS via openFDA, reports through July 30, 2026
Which of them have the most gait disturbance reports in FAERS?
Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; MedDRA preferred term “Gait Disturbance”
What next?
- Side effects across medicines
- every reaction on PlainMeds
- Report a side effect to the FDA
- MedWatch